PRX-08066

DB05607InvestigationalSmall molecule

Investigated for use/treatment in chronic obstructive pulmonary disease (COPD) and pulmonary hypertension.

Mechanism: Pharmacologically active on 5-hydroxytryptamine receptor 2B
Curator reviewed
Primary indication: Investigated for use/treatment in chronic obstructive pulmonary disease (COPD) and pulmonary hypertension.Curator reviewed
Formula / weight: C₂₃H₂₁ClFN₅O₄S · 517.96 g/mol (avg)
Also known as: 5-((4-(6-CHLOROTHIENO(2,3-D)PYRIMIDINE-4-YLAMINO)PIPERIDIN-1-YL)METHYL)-2-FLUOROBENZONITRILE MONOFUMURATE · 5-((4-(6-chlorothieno[2,3-d]pyrimidine-4-ylamino)piperidin-1-yl)methyl)-2-fluorobenzonitrile monofumurate
Code names: PRX-08066

Resolves to

Compound

Structure

InChIKeyRPYIKXHIQXRXEM-WLHGVMLRSA-NSMILESOC(=O)\C=C\C(O)=O.FC1=C(C=C(CN2CCC(CC2)NC2=C3C=C(Cl)SC3=NC=N2)C=C1)C#N

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

680Drug interactionsStructured to mechanism, not free text

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with PRX-08066, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.